Randomized phase 2 study of radiotherapy alone versus radiotherapy with paclitaxel in non-small cell lung cancer

Journal of International Medical Research

Volumn 32, Issue 4, 2004, Pages 375-383

  Sarihan, S ^a   Kayisogullari, U ^a   Ercan, I ^a   Engin, K ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Concomitant chemoradiotherapy; Non small cell lung cancer; Paclitaxel; Response rate

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; GRANISETRON; ONDANSETRON; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MEDICAL ASSESSMENT; NEUROPATHY; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PREMEDICATION; RADIATION DOSE DISTRIBUTION; RADIATION INDUCED EMESIS; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; STATISTICAL SIGNIFICANCE;

EID: 4143114696     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000403200405     Document Type: Article

References (12)

1. Emami B, Graham MV: Lung. In: Principles and Practice of Radiation Oncology, 3rd edition. (Perez CA, Brady LW eds). Philadelphia: JB Lippincott-Raven, 1998; pp1181 - 1220.
2. Non-Small Cell Lung Cancer Collaborative Group (NSCLCCG): Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899 - 909.
3. Schaake-Koning C, Vander Bogaert W, Dalesio O: Effects of concomitant cisplatin and radiotherapy on inoperable non-small cell lung cancer. N Engl J Med 1992; 326: 524 - 530.
4. Tishler RB, Schiff PB, Geard CR, Hall EJ: Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992; 22: 613 - 617.
5. Glantz MJ, Choy H, Akerley W, Kearns CM, Egorin MJ, Rhodes CH, et al: Weekly paclitaxel with and without concurrent radiation therapy; toxicity, pharmacokinetics and response. Semin Oncol 1996; 23 (Suppl 16): 128 - 135.
6. Akerley W, Choy H: Single-agent paclitaxel and radiation for non-small cell lung cancer. Semin Radiat Oncol, 1999; 9 (Suppl 1): 85 - 89.
7. Vogt HG, Kolotas C, Martin T, Schneider LV, Goes-Schmieder R, Diergarten K, et al: Concurrent paclitaxel/radiotherapy in locally advanced stage IIIA/B non-small cell lung cancer: Results of a clinical phase I study. Semin Radiat Oncol 1997; 7 (Suppl 1): S19 - S24.
8. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 1997; III: 1710 - 1717.
9. Sarihan S, Darendeliler E, Kizir A, Tuncel N, Oral EN, Karadeniz A, et al: A phase II trial, feasibility of combination of daily cisplatinum and accelerated radiotherapy via concomitant boost in stage III non-small cell lung cancer. Lung Cancer 1998; 20: 37 - 46.
10. Choy H, Yee L, Cole BF: Combined modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation. Semin Oncol 1995; 22 (Suppl 15): 38 - 44.
11. Kirkbride P, Gelmon K, Eisenhauer E, Fisher B, Dulude H: A phase I/II study of paclitaxel (Taxol) and concurrent radiotherapy in advanced nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1997; 39: 1107 - 1111.
12. Choy H, LaPorte K, Knill-Selby E, Mohr P, Shyr Y: Esophagitis in combined modality therapy for locally advanced non-small cell lung cancer. Semin Radiat Oncol 1999; 9 (Suppl 1): 90 - 96.